Results 221 to 230 of about 145,000 (257)

Evaluation of a surrogate marker: validity and efficiency

Statistics in Medicine, 2012
Statistical validation of a surrogate endpoint or surrogate marker has been studied for three decades. However, there is still no consensus on how to evaluate surrogate endpoints or surrogate markers. There is much confusion on which method should be used for the evaluation of a surrogate endpoint or surrogate marker.
openaire   +2 more sources

[Surrogate marker for ABeta42].

Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 2010
Currently, therapeutic intervention for Alzheimer disease (AD) after the disease onset is not very effective because progressive neuronal death precedes clinical symptoms. Available medicines such as AchE inhibitors transiently slow the progression of the symptoms, but they do not inhibit the pathological process.
Masayasu, Okochi, Shinji, Tagami, Kanta, Yanagida, Masatoshi, Takeda   +3 more
openaire   +1 more source

Evaluating surrogate markers.

Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1995
We discuss approaches for efficiently evaluating potential surrogate markers; in particular, we focus on case-cohort designs in which marker evaluation is undertaken only for a random sample of subjects within a randomized trial and for all other subjects who develop a major clinical outcome.
M D, Hughes, V, DeGruttola, S L, Welles
openaire   +1 more source

Evaluation of longitudinal surrogate markers

Biometrics, 2021
Layla Parast, Denis Agniel
exaly  

Testing for heterogeneity in the utility of a surrogate marker

Biometrics, 2023
Tianxi Cai, Lu Tian, Layla Parast
exaly  

Surrogate markers

Inpharma Weekly, 1998
openaire   +1 more source

Surrogate Marker

Ophthalmology, 2008
openaire   +1 more source

Surrogate Markers and Clinical Outcomes

JAMA
Jeffrey, Siegel, Mary, Thanh Hai, Peter, Stein   +2 more
openaire   +4 more sources

Quantifying the feasibility of shortening clinical trial duration using surrogate markers

Statistics in Medicine, 2021
Florence T Bourgeois, Xuan Wang, Tianxi Cai   +2 more
exaly  

Evaluating multiple surrogate markers with censored data

Biometrics, 2021
Tianxi Cai, Lu Tian, Layla Parast
exaly